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In the prevention and treatment of COVID-19 in the United States (US) 74% trust their 
health care providers. (1)  In 2021 there have been  more than 560,000 prescriptions (2) of 
hydroxychloroquine for the prevention, post-exposure prophylaxis (PEP) and treatment of 
COVID-19.  Last year, the >890,000 prescriptions were 9-fold greater than previous years, 
leading to major shortages for the approved indications of autoimmune diseases. (3)   Biological 
mechanisms support inhibition of the virus that causes COVID-19. (4) 
 
Some case series lacking 
comparison groups, claims databases, and observational studies, (3) all of which have 
confounding by indication, reported possible benefits. (5,6) Randomized trials published in high 
quality peer-reviewed journals, which provide the most reliable evidence to detect the most 
plausible small to moderate effects, hd  shown disappointing results. (3,5,6) 
When the totality of evidence is incomplete, it is appropriate for health care providers to 
remain uncertain. (5)  Nonetheless, regulatory authorities are sometimes compelled to act on 
incomplete evidence. On March 28, 2020, the US Food and Drug Administration (FDA) issued 
an Emergency Use Authorization (EUA) for hydroxychloroquine in COVID-19. By April 24, 
2020, the FDA issued a Drug Safety Communication warning about potentially fatal 




         
In this Commentary we review the recent major randomized, double-blind, placebo-
controlled trials of hydroxychloroquine in post-exposure prophylaxis and hospitalized patients, 
addressing the primary endpoint of SARS-Cov-2 infections, as well as their meta-analyses.  We, 
thus,  provide updated perspectives on benefits and risks.   
 
Hydroxychloroquine in Post-Exposure Prophylaxis 
One randomized, double-blind, placebo-controlled trial included 821 post-exposure 
prophylaxis subjects, of whom 107 developed COVID-19 over 14 days.  The 49 of 414 (11.8%) 
assigned hydroxychloroquine and 58 of 407 (14.3%) given placebo resulted in a nonsignificant 
relative risk (RR) of 0.83 (P=0.35). Overall, 140 of 349 (40.1%) assigned hydroxychloroquine 
reported a side effect by day five, as compared with 50 of 352 (16.8%) assigned placebo, a 
highly significant increase. (P<0.001). Nausea, loose stools, and abdominal discomfort were the 
most common and there were no serious intervention-related adverse effects. (8) 
In another study, among 2,314 healthy contacts of 672 Covid-19 index cases, 1,116 were 
randomized to hydroxychloroquine and 1,198 to usual care. COVID-19 occurred among 5.7% 
assigned to hydroxychloroquine and 6.2% to usual care, yielding a nonsignificant RR of 0.89 
[95% CI, 0.54 to1.46].  Adverse events were significantly higher in hydroxychloroquine (51.6%) 
compared to usual care (5.9%) but there were no reported cardiac arrhythmias. (9) 
In the most recently published trial, 671 households were randomly assigned: 337 (407 
participants) to hydroxychloroquine and 334 (422 participants) to the control group. By day 14, 
there were 53 events in hydroxychloroquine and 45 among usual care yielding a nonsignificant 
RR= 1.10 [95% CI, 0.73 to 1.66]; P > 0.20). The frequency of participants experiencing adverse 
         
events was significantly higher in the hydroxychloroquine group than the control group (66 
[16.2%] versus 46 [10.9%]; P = 0.026). (10) 
Hydroxychloroquine in Hospitalized patients 
One trial was terminated early by the external, independent Data Monitoring Committee 
due to lack of efficacy and futility.   Death within 28 days occurred in 421 patients (27%) in the 
hydroxychloroquine group and in 790 (25%) in the usual-care group yielding a nonsignificant 
RR=1.09 (95% CI, 0.97 to 1.23; P=0.15).  Patients assigned hydroxychloroquine were 
significantly less likely to be discharged from the hospital alive within 28 days than those in 
usual care (59.6% vs. 62.9%; RR=0.90; CI, 0.83 to 0.98). Among the patients not dependent on 
mechanical ventilation at baseline, those in the hydroxychloroquine group had a significantly 
higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; RR= 1.14; 95% 
CI, 1.03 to 1.27). There were no significant differences in new major cardiac arrhythmias (11) 
At 405 hospitals in 30 countries, of 11,330 patients, 2750 were assigned to remdesivir, 
954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 
651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94-96% midway 
through treatment, with 2-6% crossover. Of 1253 deaths reported, 301 were among those 
assigned to remdesivir and 303 among its control yielding a nonsignificant RR=0.95 (95% CI, 
0.81 to 1.11, P=0.50). Further, there were 104 deaths among those assigned hydroxychloroquine 
and in 84 among its control yielding a nonsignificant RR=1.19 (95% CI, 0.89 to 1.59; P=0.23). 
There were 148 deaths in patients assigned lopinavir and 146 among its control yielding a 
nonsignificant RR=1.00 (95% CI, 0.79 to 1.25; P=0.9).  Finally, there were 243 deaths among 
patients assigned interferon and 216 receiving its control yielding a nonsignificant RR=1.16 
         
(95% CI, 0.96 to 1.39; P=0.11). No drug definitely reduced mortality, overall or in any 
subgroup, or reduced initiation of ventilation or hospitalization duration. (12)  
 
Meta-analyses of Hydroxychloroquine in Post-Exposure Prophylaxis and COVID-19 
Hospitalizations 
The quality and usefulness of any meta-analysis depends on the quality and comparability 
of data from the component trials. Combined trials should have reasonably high adherence and 
follow-up rates, and use comparable drugs, doses, and outcomes. The characteristics of  
participants and the magnitude of effects should be qualitatively similar.  Such meta-analyses can 
be hypothesis testing if each component trial was designed a priori to test the same issue. In 
other circumstances such as smaller or heterogeneous trials, meta-analyses are hypothesis 
generating. Meta-analyses of observational studies are only useful to formulate but not test 
hypotheses.  They reduce the role of chance but always introduce bias as well as uncontrolled 
and uncontrollable confounding because the individual trials are not randomized. (13) 
 Our meta-analysis of hydroxychloroquine in post-exposure prophylaxis indicates a 
nonsignificant RR= 0.90 (95% CI 0.69 to 1.17). Thus, there is a statistically nonsignificant 
estimated 10% reduction in SARS-CoV-2 infection, but with sufficient precision to rule out as 
large as 20% reduction.  
Our meta-analysis of hydroxychloroquine in hospitalized patients with COVID-19 yields 
a nonsignificant RR= 1.10 (95% CI 0.99 to 1.23). In hospitalized patients, there is an 
approximate statistically nonsignificant estimated 10% increase in mortality, but with sufficient 
precision to rule out as small as a 1% reduction. Further, these data suggest equality, but the 
point estimate is in the direction of small harm on mortality.  
         
Conclusion 
    Previously, we recommended a moratorium to healthcare providers concerning 
prescriptions of hydroxychloroquine. (1)  Since that time, no significant benefits have been 
found in the recent randomized evidence for post-exposure prophylaxis and among hospitalized 
patients.  Regarding risk, hydroxychloroquine derived a reassuring safety profile from decades of 
prescriptions for autoimmune diseases of greater prevalence in younger and middle-aged women, 
whose risks of fatal outcomes due to QTc prolongations are very low.  In contrast, the risks 
associated with COVID-19 are much higher because mortality rates for COVID-19 and the side 
effects of hydroxychloroquine are both highest in older patients and those with comorbidities, 
both of whom are predominantly men. The current totality of evidence more strongly supports 
our previous recommendations concerning the lack of efficacy and possible harm of 
hydroxychloroquine in the treatment and prevention of COVID-19. (3) 
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